Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma.
Azoospermia
BRAF
CTLA-4, Cytotoxic T-Lymphocyte antigen-4
ICI, immune checkpoint inhibitor
Immunotherapy
Infertility
Male
SA, semen analysis
immune Checkpoint inhibitor therapy
mTESE, microscopic testicular sperm extraction
Journal
Urology case reports
ISSN: 2214-4420
Titre abrégé: Urol Case Rep
Pays: United States
ID NLM: 101626357
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
15
09
2020
revised:
02
11
2020
accepted:
05
11
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
11
12
2020
Statut:
epublish
Résumé
Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10-15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated.
Identifiants
pubmed: 33299797
doi: 10.1016/j.eucr.2020.101488
pii: S2214-4420(20)30377-6
pmc: PMC7704337
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101488Informations de copyright
© 2020 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Références
Oncotarget. 2017 Feb 7;8(6):10714-10725
pubmed: 27801671
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Fertil Steril. 2015 Nov;104(5):1099-103.e1-3
pubmed: 26263080
J Am Acad Dermatol. 2016 Sep;75(3):528-534
pubmed: 27543212
J Hum Reprod Sci. 2015 Oct-Dec;8(4):191-6
pubmed: 26752853